

REMARKS/ARGUMENTS

I. Status of the Claims

Claims 1-32 were originally filed. Claims 1-32 were subject to a Restriction Requirement. After response to the Restriction Requirement, claims 1 and 3-32 are elected for prosecution. Claims 1 and 2 are amended to correct typographical and punctuation mistakes. Claims 1, 2, 19, 21, 26, 27, and 29-32 are amended to recite proper Markush groups. Claims 2, 5-13, 15-18, 22-23, and 31 are amended to replace “Edg-2” with “Edg-3” receptor. Claim 28 is amended to correct punctuation mistakes. Claim 28 is also amended to recite a proper Markush group and change claim dependency. Claims 29-32 are amended to make the claims clear and concise. New claims 33-42 are added. New claims 33-42 are directed to particular species of Formulae III and IV and are readable on the elected species. No new matter has been added. Support for the new claims may be found throughout the specification.


II. Response to the Restriction Requirement

The claims are restricted into two groups. Applicants elect Group I for prosecution on the merits. The claims of Group I are drawn to a process of modulating an Edg-3 receptor mediated biological activity with Formula (I). Claims 1 and 3-32 fall within Group I. New claims 33-42 also fall within Group I.

The election of the claims of Group I is made with traverse. The claims emerge from a common inventive concept; a process of modulating an Edg-3 receptor mediated biological activity with compounds of Formula (I) and a process of modulating an Edg-3 receptor mediated biological activity with compounds of Formula (II). The Applicants respectfully submit that searching the process of modulating an Edg-3 receptor mediated biological activity with compounds of Formula (I) and the process of modulating an Edg-3 receptor mediated biological activity with compounds of Formula (II) would not be an undue burden on the Examiner.

III. Response to the Election of Species Requirement

The Examiner has required the Applicants to elect a single species and a disease condition in which the identity of each claim element is explicitly set forth. Applicants' elect compound 117 which is set forth below:



Applicants also elect cardiovascular disease as the disease condition. Cardiovascular disease includes but is not limited to ischemia and atherosclerosis.

Applicants submit that pending claims 1 and 3-32 and new claims 33-42 are readable on the elected species.

Applicants respectfully submit that such elections are without prejudice and expressly reserve the right to prosecute the non-elected species and claims at a later stage.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

Appl. No. 10/760,064
Amtd. dated October 24, 2006
Office Action dated April 25, 2006

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-442-1000.

Respectfully submitted,



Alok Goel (Reg. No. 51,745) on behalf of
Thomas D. Kohler (Reg. No. 32,797)

MORGAN, LEWIS & BOCKIUS, LLP
Two Palo Alto Square
3000 El Camino Real, Ste. 700
Palo Alto, CA 94306
Tel. (415) 442-1000
Direct Dial: (415) 442-1433
eFAX: (650) 843-4001
e-mail: agoel@morganlewis.com